Azenta announces investments to advance GENEWIZ gene synthesis capabilities

AZTA•2026-10-30

Azenta announced an exclusive licensing agreement with Elegance Corp. and the acquisition of Synplexity to expand its GENEWIZ gene synthesis capabilities. It said additional details will be provided during its Q4 fiscal 2026 earnings call.

1. Gene synthesis investments

Azenta announced an exclusive licensing agreement with Elegance Corp. and said it bought Synplexity to expand its gene synthesis capabilities. The company plans to provide additional details during its Q4 fiscal 2026 earnings call.

Azenta announces investments to advance GENEWIZ gene synthesis capabilities

1. Gene synthesis investments

Related News

B. Riley cuts Core Scientific target price to $31 from $42

Imperial Oil beats profit estimates on stronger refining margins

Verra Mobility Q3 revenue beats on government solutions segment growth

Neo-Concept swings to first-half net loss of HKD 9.1 million

India bonds buckle for fourth straight month on oil's climb